Controversy in the use of high dose systemic steroids in the acute care of patients with Stevens-Johnson syndrome

International Ophthalmology Clinics

Volumn 45, Issue 4, 2005, Pages 25-48

  Hynes, Alla Y ^a   Kafkala, Crysanthi ^a   Daoud, Yassine J ^a   Foster, C Stephen ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALLOPURINOL; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIMALARIAL AGENT; ANTIVIRUS AGENT; CIPROFLOXACIN; CORTICOSTEROID; CORTISONE; DEXAMETHASONE; EYE DROPS; HYDROCORTISONE; METHYLPREDNISOLONE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; PREDNISONE; SULFONAMIDE; THEOPHYLLINE; VACCINE;

ACUTE DISEASE; CLINICAL FEATURE; CLINICAL PRACTICE; CORTICOSTEROID THERAPY; CUSHINGOID SYNDROME; DISEASE COURSE; DRUG MEGADOSE; ERYTHEMA MULTIFORME; EVIDENCE BASED MEDICINE; EYE DISEASE; GENETIC PREDISPOSITION; HISTOPATHOLOGY; HUMAN; HYPERGLYCEMIA; HYPOKALEMIA; IMMUNIZATION; INCIDENCE; INFECTION; INFECTIOUS COMPLICATION; LUNG DISEASE; MORTALITY; MYCOPLASMA PNEUMONIAE; NEPHRITIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SKIN BIOPSY; STEVENS JOHNSON SYNDROME; THROMBOCYTOPENIC PURPURA; TOXIC EPIDERMAL NECROLYSIS; TREATMENT OUTCOME; VIRUS INFECTION;

ACUTE DISEASE; CONJUNCTIVAL DISEASES; GLUCOCORTICOIDS; HUMANS; INFUSIONS, INTRAVENOUS; METHYLPREDNISOLONE; PRACTICE GUIDELINES; STEVENS-JOHNSON SYNDROME;

EID: 27544474632     PISSN: 00208167     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.iio.0000177430.89645.6d     Document Type: Review

References (72)

1. Von Hebra F. On Diseases of the Skin Including the Exanthema, vol 1. Translated by Fagge CH. London: New Sydenham Sociey; 1866:285-289.
2. Stevens AM, Johnson FC. A new eruptive fever associated with stomatitis and ophthalmia. Report of two cases in children. Am J Dis Child. 1922;24:526-533.
3. Lyell A. Toxic epidermal necrolysis: an eruption resembling scalding of the skin. Br J Dermatol 1956;68:355-361.
4. Leaute-Labreze C, Lamireau T, Chawki D, et al. Diagnosis, classification, and management of the erythema multiforme and Stevens-Johnson Syndrome. Arch Dis Child. 2000;83:347-352.
5. Kawasaki S, Nishida K, Sotozono C, et al. Conjunctival inflammation in the chronic phase of Stevens-Johnson syndrome. Br J Ophthalmol 2000;84:1191-1193.
6. Sane SP, Bhatt AD. Stevens-Johnson syndrome-challenges of recognition and management. J Assoc Physicians India. 2000;48:999-1003.
7. Wolkenstein P, Revuz J. Drug-induced severe skin reactions. Incidence, management and prevention. Drug Saf. 1995;13:56-68.
8. Enu CC, Elegbeleye OO, Femi-Pearse D. Stevens-Johnson's syndrome in Africans. Trop Geogr Med. 1980;32:224-226.
9. Hallgren J, Tengvall-Linder M, Persson M, et al. Stevens-Johnson syndrome associated with ciprofloxacin: a review od adverse cutaneous events reported in Sweden as associated with this drug. J Am Acad Dermatol. 2003;49(Suppl):S267- S269.
10. Brook U. Stevens-Johnson syndrome and abnormal root development: a case report. Int J Paediatr Dent. 1994;4:101-103.
11. Ball R, Ball LK, Wise RP, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis after vaccination: reports to the vaccine adverse event reporting system. Pediatr Infect Dis J. 2001;20:219-223.
12. Forman R, Koren G, Shear NH, Erythema multiforme, Stevens-Johnson syndrome and Toxic epidermal necrolysis in children: a review of 10 years' experience. Drug Saf. 2002; 25:965-972.
13. Choy AC, Yarnold PR, Brown JE, et al. Virus induced erythema multiforme and Stevens-Johnson syndrome. Allergy Asthma Proc. 1995;16:157-161.
14. Jonson-Reagan L, Bahna SL. Severe drug rashes in three siblings simultaneously. Allergy. 2003;58:445-447.
15. Mondino BJ, Brown SI, Biglan AW. HLA antigens in Stevens-Johnson syndrome with ocular involvement. Arch Ophthalmol. 1982;100:1453-1454.
16. Chung WH, Hung SI, Hong HS, et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature. 2004;428:486-488.
17. Power WJ, Saidman SL, Zhang DS, et al. HLA typing in patients with ocular manifestations of Stevens-Johnson syndrome. Ophthalmology. 1996;103:1406-1409.
18. Roujeau JC, Huynh TN, Bracq C, et al. Genetic susceptibility to toxic epidermal necrolysis. Arch Dermatol. 1987;123:1171-1173.
19. Fritsch PO, Sidoroff A. Drug-induced Stevens-Johnson syndrome/toxic epidermal necrolysis. Am J Clin Dermatol 2000;1:349-360.
20. Abe R, Shimizu T, Shibaki A, et al. Toxic epidermal necrolysis and Steven-Johnson syndrome are induced by soluble Fas ligand. Am J Pathol. 2003;162:1515-1520.
21. Posadas SJ, Torres MJ, Mayorga C, et al. Gene expression levels of cytokine profile and cytotoxic markers in non-immediate reactions to drugs. Blood Cells Mol Dis. 2002;29: 179-189.
22. Czelej D, Chodorowska G, Lecewicz T. Plasma activity of interleukin-6 and some acute phase proteins in severe drug-induced skin adverse reactions. Ann Univ Mariae Curie Sklodowska [Med]. 2002;57:62-67.
23. Inachi S, Mizutani H, Shimizu M. Epidermal apoptotic cell death in erythema multiforme and Stevens-Johnson syndrome. Contribution of perforin-positive cell infiltration. Arch Dermatol 1997;133:845-849.
24. Wuepper KD, Watson PA, Kazmierowski JA. Immune complexes in erythema multiforme and the Stevens-Johnson syndrome. J Invest Dermatol. 1980;74:368-371.
25. Foster CS, Fong LP, Azar D, et al. Episodic conjunctival inflammation after Steven-Johnson syndrome. Ophthalmology. 1988;95:453-462.
26. Donta-Bakoyianni K, Mitsea AG, Deodoropoulou-Papadimitriou K. Stevens-Johnson syndrome: case presentation. J Clin Pediatr Dent. 2002;27:71-76.
27. Chabas E, Salazar F, Rovira I, et al. Stevens-Johnson syndrome associated with esophageal stenosis. Rev Esp Anestesiol Reanim. 1990;37:362-365.
28. Tsunoda N. Rapidly progressive bronchiolitis obliterans associated with Stevens-Johnson syndrome. Chest. 1990;98:243-245.
29. Morelli MS, O'Brien FX. Stevens-Johnson syndrome and cholestatic hepatitis. Dig Dis Sci 2001;46:2385-2388.
30. Suarez Garsia A, Gonzalez Hervas C. Fetal respiratory and renal manifestation of Stevens-Johnson syndrome. An Esp Pediatr. 2002;57:71-73.
31. Auran JD, Hornblass A, Gross ND. Stevens-Johnson syndrome with associated nasolacrimal duct obstruction treated with dacryocystorhinostomy and Crawford silicone tube insertion. Ophthal Plast Reconstr Surg. 1990;6:60-63.
32. Halevy S, Cohen AD, Livni E. The diagnostic role of the in vitro drug-induced interferon-gamma release test in Stevens-Johnson syndrome. Int J Dermatol. 1999;38:835-840.
33. Lebargy F, Wolkenstein P, Gisselbrecht M, et al. Pulmonary complications in toxic epidermal necrolysis: a prospective clinical study. Intensive Care Med. 1997;23:1237-1244.
34. Ginsburg CM. Stevens-Johnson syndrome in children. Pediatr Infect Dis. 1982;1:155-158.
35. Tsubota K, Satake Y, Ohyama M, et al. Surgical reconstruction of the ocular surface in advanced ocular cicatrical pemphigo and Stevens-Johnson syndrome. Am J Ophthalmol. 1996;122:38-52.
36. Dohlman CH, Terada H. Keratoprosthesis in pemphigoid and Stevens-Johnson syndrome. Adv Exp Med Biol. 1998;438:1021-1025.
37. Hockett KC. Stevens-Johnson syndrome and toxic epidermal necrolysis: oncologic considerations. Clin J Oncol Nurs. 2004;8:27-30, 55.
38. Colic-Hadzic B, Mladina N, Latifagic A, et al. The Stevens-Johnson syndrome-personal experience. Med Arch. 2002;56(Suppl 1):54-56.
39. Roujeau JC. Treatment of severe drug eruptions. J Dermatol. 1999;26:718-722.
40. Huang RY, Liu HN, Wong CK. Stevens-Johnson syndrome: a review of 42 cases. Zhonghua Yi Xue Za Zhi (Taipei). 1993;51:225-230.
41. Bjornberg A. Fifteen cases of toxic epidermal necrolysis (Lyell). Acta Derm Venereol Suppl (Stockh). 1973;53:149-152.
42. Renfro L, Grrant-Kels JM, Feder HM Jr, et al. Controversy, are systemic steroids indicated in the treatment of erythema multiforme? Pediatr Dermatol. 1989;6:43-50.
43. Patterson R, Dykewicz MS, Gonzalzles A, et al. Erythema multiforme and Stevens-Johnson syndrome. Descriptive and therapeutic controversy. Chest. 1990;98:331-336.
44. Patterson R, Grammer LC, Greenberg PA, et al. Stevens-Johnson syndrome: effectiveness of corticosteroid in management and recurrent SJS. Allergy Asthma Proc. 1992;13:89-95.
45. Patterson R, Miller M, Kaplan M, et al. Effectiveness of early therapy with corticosteroids in Stevens-Johnson syndrome: experience with 41 cases and a hypothesis regarding pathogenesis. Ann Allergy. 1994;73:27-34.
46. Tripathi A, Ditto AM, Patterson R. Corticosteroid therapy in an additional 13 cases of Stevens-Johnson syndrome: a total series of 67 cases. Allergy Asthma Proc. 2000;21:101-105.
47. Martinez AE, Atherton DA. High-dose systemic corticosteroids can arrest the recurrence of severe mucocutaneous erythema multiforme. Pediatr Dermatol. 2000;7: 87-90.
48. Barman KD, Verma KK, Agrawal S, et al. Stevens-Johnson syndrome with idiopathic thrombocytopenic purpura treated with dexamethasone pulse therapy. J Dermatol. 2003;30:54-58.
49. Jo DS, Yang JW, Hwang PH, et al. Stevens-Johnson syndrome in a boy with nephritic syndrome during prednisone therapy. Pediatr Nephrol. 2003;18:959-961. Epub 2003 Jun.
50. Kakourou T, Klonza D, Soteropoulou F, et al. Corticosteroid treatment of erythema multiforma major (Stevens-Johnson syndrome) in children. Eur J Pediatr. 1997;156: 90-93.
51. Cheriyan S, Patterson R. Recurrent Stevens-Johnson syndrome secondary to herpes simplex: a follow up on a successful management program. Allergy Asthma Proc. 1996;17: 71-73.
52. Detjen PF, Patterson R, Noskin GA, et al. Herpes simplex virus associated with recurrent Stevens-Johnson syndrome. A management strategy. Arch Intern Med. 1992; 152:1513-1516.
53. Marvine J, Heimbach D, Engrav L, et al. Improved treatment of the Stevens-Johnson syndrome. Arch Surg. 1984;119:601-605.
54. Levy M, Shear NH. Mycoplasma pneumonias infections and Stevens-Johnson syndrome. Report of eight cases and review of the literature. Clin Pediatr (Phila). 1991;30:42-49.
55. Power WJ, Ghoraishi M, Merayo-Lloves J, et al. Analysis of the acute ophthalmic manifestations of the erythema multiforme/Stevens-Johnson syndrome/toxic epidermal necrolysis disease spectrum. Ophthalmology. 1995;102:1669-1676.
56. Rasmussen JE. Erythema multiforme in children. Response to treatment with systemic corticosteroids. Br J Dermatol. 1976;95:181-186.
57. Prendivile JS, Hebert AA, Greenwald MJ, et al. Management of Stevens-Johnson syndrome and toxic epidermal necrolysis in children. J Pediatr. 1989;115:881-887.
58. Halebian P, Shires T. Burn unit treatment of acute, severe exfoliating disorders. Annu Rev Med. 1989;40:137-147.
59. Yetiv JZ, Bianchine JR, Owen JA. Etiologic factors of the Stevens-Johnson syndrome. South Med J. 1980;73:599-602.
60. Foster CS, Fong LP, Azar D, et al. Episodic conjunctival inflammation after Stevens-Johnson syndrome. Ophthalmology. 1988;95:453-462.
61. 125I Clq binding and skin immunofluorescence in erythema multiforme. J Invest Dermatol. 1980;74:375-378.
62. Bloom H, Lowel TWI. Erythema multiforme with renal and myocardial injury. Proc R Soc Med. 1964;57:175.
63. Garcia DI, LeCleach L, Bocquet H, et al. Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death? Arch Dermatol. 2000;136:323-327.
64. Morici MV, Galen WK, Shetty SK, et al. Intravenous immunoglobulin therapy for children with Stevens-Johnson syndrome. J Rheumatol. 2000;27:2494-2497.
65. Metry DW, Jung P, Levy ML. Use of intravenous immunoglobulin in children with Stevens-Johnson syndrome and toxic epidermal necrolysis. Pediatrics. 2003;112:1430-1436.
66. Bleier AH, Schwartz E. Cortisone in treating Stevens-Johnson syndrome. Am J Ophthalmol. 1951;34:618-620.
67. Wammock VS, Biederman AA, Jordan RS. Erythema multiforme exudativum (Stevens-Johnson syndrome): report on a patient treated with pituitary adrenocorticotrophic hormone. JAMA. 1951;147:637-639.
68. Agosta WN, Reeves N, Shanks ED, et al. Erythema multiforme bullosum (Stevens-Johnson syndrome). N Engl J Med. 1953;246:217-219.
69. VanderMeer R, Wilson DE, Bulthuis JE. Therapeutic effect of ACTH in Stevens-Johnson syndrome (Erythema multiforme exudativum). N Engl J Med. 1953;248:806-808.
70. Weeks VT, Lehmann WX. Erythema multiforme exudativum treated with cortisone or adrenocorticotrophic hormone. J Pediatr. 1954;44:508-515.
71. Saitoh A, Ohya T, Yoshida S, et al. A case report of Stevens-Johnson syndrome with Mycoplasma pneumoniae infection. Acta Paediatr Jpn. 1995;37:113-115.
72. Adunsky A, Steiner ZP, Eframian A. Stevens-Johnson syndrome with Mycoplasma pneumoniae infection. Cutis. 1987;40:123-124.